Macrogenics inc (MGNX)
Seite 1 von 5 Neuester Beitrag: 15.08.24 21:00 | ||||
Eröffnet am: | 23.04.17 20:51 | von: Chalifmann3 | Anzahl Beiträge: | 111 |
Neuester Beitrag: | 15.08.24 21:00 | von: Vassago | Leser gesamt: | 42.538 |
Forum: | Hot-Stocks | Leser heute: | 7 | |
Bewertet mit: | ||||
Seite: < | 2 | 3 | 4 | 5 5 > |
MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The companys advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate. In addition, the companys products include MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; and MGD014, a DART molecule that targets human immunodeficiency virus, or HIV-infected cells, and CD3-expressing T cells. It has collaboration and license agreements with Janssen Biotech, Inc.; Les Laboratoires Servier and Institut de Recherches Servier; Boehringer Ingelheim GmbH; Pfizer, Inc.; and Green Cross Corp. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
MFG
Chali
Gut,diese Biotechaktie ist jetzt nicht so super günstig,aber MGNX hat auch 300 mio cash auf der Naht,schuldenfrei,daher sollte zum leichteren Einstieg mal dieser kleine Spruch beherzigt werden: :
Durch kühne Opfer pflegen,
den Sieg Sie zu erstreben.
Oft nahm den Preis entgegen,
wer Vieles preisgegeben ...
hm ?
https://endpts.com/...-cancer-trials-as-liver-tox-spurs-safety-fears/
Positive Phase III Studiendaten
https://endpts.com/...-seller-herceptin-for-metastatic-breast-cancer/
110 Mio. $ Offering
- 5,5 Mio. Aktien zu je 20$ = ~ 110 Mio. $
- 825.000 Aktien optional
https://www.macrogenics.com/news/...-public-offering-of-common-stock/
neue Daten bei SOPHIA Brustkrebsstudie
http://ir.macrogenics.com/news-releases/...sults-phase-3-sophia-study
https://seekingalpha.com/news/...percent-new-data-breast-cancer-study
- eines der spannendsten Biotechs auf meiner Watchlist
- die Frage aller Fragen, wo und wann findet/bildet MGNX seinen Boden
https://seekingalpha.com/article/...ntial-makes-massively-undervalued
aktualisierte Überlebensdaten der Phase3 Studie
http://ir.macrogenics.com/news-releases/...verall-survival-data-phase
https://seekingalpha.com/news/...t-premarket-doubts-margetuximab-data
https://www.fool.com/investing/2019/10/23/...cs-is-tanking-today.aspx
Bin bei 10 Dollar rein, sieht gut aus...